O

Omeros Corp
D

OMER

3.84000
USD
0.25
(6.82%)
مغلق
حجم التداول
206,555
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
224,996,018
أصول ذات صلة
A
ARWR
-0.520
(-3.20%)
15.740 USD
F
FATE
-0.01000
(-0.80%)
1.23500 USD
M
MDGL
-0.49
(-0.16%)
298.42 USD
M
MRSN
-0.01490
(-4.60%)
0.30900 USD
M
MRUS
1.254
(1.91%)
66.940 USD
S
SRPT
-0.970
(-7.53%)
11.910 USD
المزيد
الأخبار المقالات

العنوان: Omeros Corp

القطاع: Healthcare
الصناعة: Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.